{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:26:58Z","timestamp":1763580418182,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can cause BP, although precise mechanism of DPP-4i-related BP remains unclear. In this report, we showed a case with appearance of various disease-specific antibodies after the onset of DPP-4i-related BP. Furthermore, various disease-specific antibodies became positive and showed high titers two years after the onset of DPP-4i-related BP and discontinuation of DPP-4i. These data showed that it is possible for immune tolerance to be broken after the onset of DPP-4i-related BP, and it may be important to check autoimmune antibodies in DPP-4i-related BP subjects even when BP symptoms are improved.<\/jats:p>","DOI":"10.3389\/fimmu.2022.843480","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T04:43:53Z","timestamp":1646282633000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuichiro","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Anno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14649","article-title":"Increased Prevalence of Diabetes Mellitus in Bullous Pemphigoid Patients During the Last Decade","volume":"32","author":"Fania","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14957","article-title":"Changing Prevalence of Diabetes Mellitus in Bullous Pemphigoid: It Is the Dipeptidyl Peptidase-4 Inhibitors","volume":"32","author":"Gravani","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050822","article-title":"NIDDM as a Disease of the Innate Immune System: Association of Acute-Phase Reactants and Interleukin-6 With Metabolic Syndrome X","volume":"40","author":"Pickup","year":"1997","journal-title":"Diabetologia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous Pemphigoid and Dipeptidyl Peptidase IV Inhibitors: A Case-Noncase Study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.09.001","article-title":"B-Cell Tolerance Checkpoints in Health and Autoimmunity","volume":"20","author":"Meffre","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000034509.14906.ae","article-title":"Inflammatory Cytokine Concentrations are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress","volume":"106","author":"Esposito","year":"2002","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14228","article-title":"The Role of Dipeptidyl Peptidase-4 in Cutaneous Disease","volume":"30","author":"Patel","year":"2021","journal-title":"Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1423.042","article-title":"Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses","volume":"1110","author":"Reinhold","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes May Reduce the Risk of Autoimmune Diseases: A Population-Based Cohort Study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-9005-8","article-title":"Is There an Association Between Dipeptidyl Peptidase-4 Inhibitors and Autoimmune Disease? A Population-Based Study","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13955","article-title":"Dipeptidyl Peptidase-4 Inhibitors Lower the Risk of Autoimmune Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Population-Based Cohort Study","volume":"85","author":"Seong","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01533-5","article-title":"Dipeptidyl Peptidase-4 Inhibitors and the Risks of Autoimmune Diseases in Type 2 Diabetes Mellitus Patients in Taiwan: A Nationwide Population-Based Cohort Study","volume":"57","author":"Chen","year":"2020","journal-title":"Acta Diabetol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i9.1426","article-title":"Dipeptidyl Peptidase-4 Inhibitor-Induced Autoimmune Diseases: Current Evidence","volume":"12","author":"Roy","year":"2021","journal-title":"World J Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1568-9972(03)00006-5","article-title":"The Epidemiology of Autoimmune Diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1468-3083.2002.00504.x","article-title":"Pemphigus Vulgaris: A Review of Treatment Over a 19-Year Period","volume":"16","author":"Ljubojevi\u0107","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.843480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T04:43:57Z","timestamp":1646282637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.843480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2022.843480"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.843480","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"article-number":"843480"}}